Company intelligence / Profile preview

Model Medicines

La Jolla, California, United Statesmodelmedicines.com ↗

Ownership: Private
Development stage: Preclinical

Overview

MDL-001, their lead antiviral compound, has completed two Phase 1 clinical trials with ~100 healthy subjects, demonstrating safety and tolerability at doses up to 200 mg/day for 28 days. The compound shows broad-spectrum antiviral activity with favorable pharmacokinetics including lung accumulation 10-40 times higher than EC50 values[3].

Therapeutic areas: GastroenterologyMetabolic DisordersOncologyNeurologyInfectious Diseases
Modalities: Small molecules
Industry: Biotech

Drug pipeline

5 assets

MDL-4102

Preclinical

4 more assets in the full pipeline.

Request access →

Partnerships

Validated by researchers at academic and corporate laboratories

Beyond the preview

Go deeper on Model Medicines.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Model Medicines.

Explore the full profile